- Home
- CRIS vs COCP Comparison
CRIS vs COCP Comparison
Compare CRIS & COCP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRIS
- COCP
- Stock Information
- Founded
- CRIS 2000
- COCP 2006
- Country
- CRIS United States
- COCP United States
- Employees
- CRIS N/A
- COCP N/A
- Industry
- CRIS Biotechnology: Biological Products (No Diagnostic Substances)
- COCP Biotechnology: Pharmaceutical Preparations
- Sector
- CRIS Health Care
- COCP Health Care
- Exchange
- CRIS Nasdaq
- COCP Nasdaq
- Market Cap
- CRIS 13.5M
- COCP 15.4M
- IPO Year
- CRIS 2000
- COCP N/A
- Fundamental
- Price
- CRIS $1.96
- COCP $1.57
- Analyst Decision
- CRIS Strong Buy
- COCP Strong Buy
- Analyst Count
- CRIS 3
- COCP 1
- Target Price
- CRIS $21.00
- COCP $7.00
- AVG Volume (30 Days)
- CRIS 99.1K
- COCP 13.0K
- Earning Date
- CRIS 05-06-2025
- COCP 05-20-2025
- Dividend Yield
- CRIS N/A
- COCP N/A
- EPS Growth
- CRIS N/A
- COCP N/A
- EPS
- CRIS N/A
- COCP N/A
- Revenue
- CRIS $11,202,000.00
- COCP N/A
- Revenue This Year
- CRIS $4.67
- COCP N/A
- Revenue Next Year
- CRIS $9.77
- COCP N/A
- P/E Ratio
- CRIS N/A
- COCP N/A
- Revenue Growth
- CRIS 14.17
- COCP N/A
- 52 Week Low
- CRIS $1.02
- COCP $1.12
- 52 Week High
- CRIS $16.93
- COCP $3.26
- Technical
- Relative Strength Index (RSI)
- CRIS 50.58
- COCP 54.11
- Support Level
- CRIS $1.85
- COCP $1.44
- Resistance Level
- CRIS $2.25
- COCP $1.65
- Average True Range (ATR)
- CRIS 0.27
- COCP 0.18
- MACD
- CRIS 0.04
- COCP 0.01
- Stochastic Oscillator
- CRIS 41.73
- COCP 57.76
About CRIS Curis Inc.
Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.
About COCP Cocrystal Pharma Inc.
Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first and in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI).